[1] |
Bunn PA Jr, Minna JD, Augustyn A, et al. Small Cell Lung Cancer: Can Recent Advances in Bi ology and Molecular Biology Be Translated into Improved Outcomes?[J]. J Thorac Oncol, 2016, 11(4): 453-474. DOI:10.1016/j.jtho.2016.01.012 |
|
[2] |
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016[J]. CA Cancer J Clin, 2016, 66(1): 7-30. DOI:10.3322/caac.21332 |
|
[3] |
Shi Y, Hu Y, Hu X, et al. Cisplatin combined with irinotecan or etoposide for untreated extensive-stage small cell lung cancer: A multicenter randomized controlled clinical trial[J]. Thorac Cancer, 2015, 6(6): 785-791. DOI:10.1111/1759-7714.12303 |
|
[4] |
Tiseo M, Boni L, Ambrosio F, et al. Italian multicenter phase Ⅲ randomized study of cisplatin-etoposide with or without bevacizumab as first-line treatment in extensive stage small cell lung cancer: treatment rationale and protocol design of the GOIRC-AIFA FARM6PMFJM trial[J]. Clin Lung Cancer, 2015, 16(1): 67-70. |
|
[5] |
Saunders LR, Bankovich AJ, Anderson WC, et al. A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo[J]. Sci Transl Med, 2015, 7(302): 302ra136. DOI:10.1126/scitranslmed.aac9459 |
|
[6] |
Tanaka K, Isse K, Fujihira T, et al. Prevalence of Delta-like protein 3 expression in patients with small cell lung cancer[J]. Lung Cancer, 2018, 115: 116-120. DOI:10.1016/j.lungcan.2017.11.018 |
|
[7] | |
|
[8] |
胡冰心, 叶健斌, 邱晓媚, 等. 过表达DLL3促进人胃癌细胞的增殖[J]. 南方医科大学学报, 2018, 38(1): 14-19. [Hu BX, Ye JB, Qiu XM, et al. Over-expresson of human notch ligand Delta-like 3 promotes proliferation of human gastric cancer cells in vitro[J]. Nanfang Yi Ke Da Xue Xue Bao, 2018, 38(1): 14-19.] |
|
[9] |
Mullendore ME, Koorstra JB, Li YM, et al. Ligand-dependent Notch signaling is involved in tu mor initiation and tumor maintenance in pancreatic cancer[J]. Clin Cancer Res, 2009, 15(7): 2291-2301. DOI:10.1158/1078-0432.CCR-08-2004 |
|
[10] |
Rudin CM, Pietanza MC, Bauer TM, et al. Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study[J]. Lancet Oncol, 2017, 18(1): 42-51. DOI:10.1016/S1470-2045(16)30565-4 |
|
[11] |
Henke RM, Meredith DM, Borromeo MD, et al. Ascl1 and Neurog2 form novel complexes and regulate Delta-like3 (Dll3) expression in the neural tube[J]. Dev Biol, 2009, 328(2): 529-540. DOI:10.1016/j.ydbio.2009.01.007 |
|
[12] |
Sharma SK, Pourat J, Abdel-Atti D, et al. Noninvasive Interrogation of DLL3 Expression in Metastatic Small Cell Lung Cancer[J]. Cancer Res, 2017, 77(14): 3931-3941. DOI:10.1158/0008-5472.CAN-17-0299 |
|
[13] |
Williams SA, Anderson WC, Santaguida MT, et al. Patient-derived xenografts, the cancer stem cell paradigm, and cancer pathobiology in the 21st century[J]. Lab Invest, 2013, 93(9): 970-982. DOI:10.1038/labinvest.2013.92 |
|
[14] |
Konstantakou EG, Velentzas AD, Anagnostopoulos AK, et al. Deep-proteome mapping of WM-266-4 human metastatic melanoma cells: From oncogenic addiction to druggable targets[J]. PLoS One, 2017, 12(2): e171512. |
|
[15] |
Jia L, Zhang S, Ye Y, et al. Paclitaxel inhibits ovarian tumor growth by inducing epithelial cancer cells to benign fibroblast-like cells[J]. Cancer Lett, 2012, 326(2): 176-182. DOI:10.1016/j.canlet.2012.08.004 |
|
[16] |
Suda K, Tomizawa K, Fujii M, et al. Epithelial to mesenchymal transition in an epidermal growth factor receptor-mutant lung cancer cell line with acquired resistance to erlotinib[J]. J Thorac Oncol, 2011, 6(7): 1152-1161. DOI:10.1097/JTO.0b013e318216ee52 |
|
[17] |
Arumugam T, Ramachandran V, Fournier KF, et al. Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer[J]. Cancer Res, 2009, 69(14): 5820-5828. DOI:10.1158/0008-5472.CAN-08-2819 |
|
[18] |
Chapman G, Sparrow DB, Kremmer E, et al. Notch inhibition by the ligand DELTA-LIKE 3 defines the mechanism of abnormal vertebral segmentation in spondylocostal dysostosis[J]. Hum Mol Genet, 2011, 20(5): 905-916. DOI:10.1093/hmg/ddq529 |
|
[19] |
Chen Y, Wang Z, Chang P, et al. The effect of focal adhesion kinase gene silencing on 5-fluorouracil chemosensitivity involves an Akt/NF-kappaB signaling pathway in colorectal carcinomas[J]. Int J Cancer, 2010, 127(1): 195-206. |
|
[20] | |
|
[21] |
Koshkin VS, Garcia JA, Reynolds J, et al. Transcriptomic and Protein Analysis of Small-cell Bladder Cancer (SCBC) Identifies Prognostic Biomarkers and DLL3 as a Relevant Therapeutic Target[J]. Clin Cancer Res, 2019, 25(1): 210-221. DOI:10.1158/1078-0432.CCR-18-1278 |
|
[22] |
Yan LX, Liu YH, Li Z, et al. Prognostic value of delta-like protein 3 combined with thyroid transcription factor-1 in small-cell lung cancer[J]. Oncol Lett, 2019, 18(3): 2254-2261. |
|
[23] |
冀瑛瑛, 申淑景, 卢畅, 等. 晚期小细胞肺癌组织TTF-1表达与一线含铂方案化疗敏感性及预后相关性分析[J]. 中华肿瘤防治杂志, 2017, 24(22): 1578-1583. [Ji YY, Shen SJ, Lu C, et al. Correlation analysis between TTF-1 expression and chemosensitivity and prognosis of advanced small cell lung cancer patients treated with first-line platinum-based chemotherapy[J]. Zhonghua Zhong Liu Fang Zhi Za Zhi, 2017, 24(22): 1578-1583.] |
|
[24] |
滕悦, 袁成, 朱爱玲. 血清ProGRP和NSE在小细胞肺癌化疗疗效评价中的应用价值[J]. 临床和实验医学杂志, 2017, 16(24): 2440-2442. [Teng Y, Yuan C, Zhu AL. The value of serum proGRP and NSE in the evaluation of the efficacy and prognosis of chemotherapy for small cell lung cancer patients[J]. Lin Chuang He Shi Yan Yi Xue Za Zhi, 2017, 16(24): 2440-2442.] |
|
[25] |
黄宗华, 徐丹丹, 张飞艳, 等. 血清ProGRP和NSE对评价小细胞肺癌化疗疗效及其预后的价值[J]. 中华肿瘤防治杂志, 2015, 22(22): 1774-1778. [Huang ZH, Xu DD, Zhang FY, et al. Utility of ProGRP and NSE in therapy monitoring and prognosis evaluation in patients with small cell lung cancer[J]. Zhonghua Zhong Liu Fang Zhi Za Zhi, 2015, 22(22): 1774-1778.] |
|